CMS Releases List of Drugs for Medicare Price Negotiation





- Aug 1
Using Technology to Transform Specialty Medication Access and Affordability


- Mar 24
Tis Full and Very, Very Expensive: the 2023 Specialty Drug Pipeline | AMCP 2023

- Feb 14
Exclusive: Profiling Manufacturers’ Limited and Exclusive Pharmacy Networks for Specialty Drugs


- Oct 14, 2022
How to Make Accumulator, Maximizer Programs More Acceptable to Your Patients l AMCP Nexus 2022

- Aug 23, 2022
High-Concentration Version of Adalimumab Biosimilar Will Be Available in 2023

- Jul 21, 2022
California Initiative Provides $100 Million to Produce Its Own Insulin Biosimilars

- Jul 16, 2022
Biogen/ICER experts tussle over Aduhelm as cost watchdogs unanimously slap down new Alzheimer's drug

- Jun 22, 2022
How Will Payers Manage Multiple Adalimumab Biosimilars? Jeffrey Casberg Explains


- Jun 1, 2022
6 Payor Tactics to Control Drug Spending


- Jun 1, 2022
Data on Adalimumab Biosimilar Confirm Equivalence of Low- and High-Concentration Formulations

- May 30, 2022
New Phase Will Increase Trajectory of Biosimilar Use in the United States, Expert Says

- May 26, 2022
Payer Management Tools and Trends for Biosimilars in the US


- Apr 12, 2022
Expert Opinion: What Factors Will Have the Greatest Impact on US Adoption of Humira Biosimilars?


- Apr 1, 2022
Upcoming Generics Provide New Considerations and Opportunities for Savings

- Mar 29, 2022
Jeffery Casberg Previews His Presentations at AMCP 2022


- Mar 25, 2022
Data, Disparities, Drug Pricing Take Center Stage at AMCP 2022


- Nov 18, 2021
How Cost-Effective Are New Drugs for Myasthenia Gravis? An ICER Review Weighs the Options


- Nov 1, 2021
IPD Executive Offers Perspective on Biosimilar Uptake and Policy


- Nov 1, 2021
Pharmacy Policy Experts Describe Changes in Biosimilar Adoption Curve